Also, the ALS–FTLD-associated p62/SQSTM1 P348L and G351A mutations impair Keap1 binding, resulting in reduced Nrf2 signaling and aberrant expression of oxidative response genes48. The gene discussed is SQSTM1; the disease is amyotrophic lateral sclerosis.